Skip to content Skip to footer
Subscribe Now
Viewpoints_Daniel A. de Boer
VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)

In an interview with PharmaShots, Daniel A. de Boer, Founder, and CEO at ProQR shared his views on the P-II/III Illuminate study of sepofarsen for the treatment of leber congenital amaurosis (LCA10)Shots:The ongoing P-II/III Illuminate study evaluates sepofarsen in 36 adults and children aged ≥8yrs. with LCA10. The results are expected in late Q1 or early Q2’22In the P-I/II clinical…
November 23, 2021

Read more

Viewpoints_Daniel A. de Boer
VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10)Shots:The Illuminate P-II/III trial of sepofarsen is a double-masked, randomized, controlled, multiple-dose study to evaluate if sepofarsen is effective at improving vision and is…
March 8, 2021

Read more